Jpmorgan Chase & CO Compugen LTD Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Compugen LTD stock. As of the latest transaction made, Jpmorgan Chase & CO holds 180,772 shares of CGEN stock, worth $296,466. This represents 0.0% of its overall portfolio holdings.
Number of Shares
180,772
Previous 71,132
154.14%
Holding current value
$296,466
Previous $183,000
65.57%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CGEN
# of Institutions
73Shares Held
13.3MCall Options Held
191KPut Options Held
135K-
Silverarc Capital Management, LLC1.5MShares$2.46 Million0.72% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.29MShares$2.11 Million0.0% of portfolio
-
Taylor Frigon Capital Management LLC1.2MShares$1.97 Million1.09% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl1.09MShares$1.79 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C31.02MShares$1.67 Million0.0% of portfolio
About COMPUGEN LTD
- Ticker CGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 86,624,600
- Market Cap $142M
- Description
- Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...